Catalent wins ‘Innovation in Process and Formulation Development’ award at CPHI Worldwide for its OptiShell softgel technology
![](/46/pdcnewsitem/03/75/72/Catalent.png)
The OptiShell softgel technology uses plant-derived polysaccharides providing scientists with new formulation opportunities.
Catalent Pharma Solutions has won the ‘Innovation in Process and Formulation Development’ category at the annual CPHI Pharma Awards, for its OptiShell softgel technology platform.
Softgel capsules have long been recognized by the pharmaceutical community and patients as effective dosage forms for oral drug delivery. Softgels traditionally use gelatin as the film-forming polymer in the capsule shell. The OptiShell softgel technology uses plant-derived polysaccharides providing scientists with new formulation opportunities.
The different physico-chemical and thermo-mechanical properties of OptiShell capsules allow for encapsulation of a wider range of fill formulation types including semi-solids formulated at higher temperatures.
Catalent’s OptiShell technology was one of three finalists selected by a panel of pharma industry experts, and the award was presented at a ceremony on 13 October, at the world’s largest pharmaceutical event, CPHI Worldwide.
“We would like to thank the judging panel for their recognition of our OptiShell softgel platform,” commented Dr Aris Gennadios, Catalent’s President of Softgel Technologies. “OptiShell technology may provide an opportunity for formulators to develop semi-solid, extended release formulations with improved and more consistent therapeutic effectiveness. The “hot-filling” process enables delivery of semi-solid formulations in a patient preferred dose form, while the semi-solid matrix offers extended release profiles that can reduce the maximum API concentration in the bloodstream, decrease the dosing frequency, and, therefore, potentially increase patient adherence.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance